Require health plan issuers and Medicaid to cover PANDAS, PANS
Impact
The implementation of HB 359 is likely to have a significant impact on state law concerning healthcare coverage for pediatric mental health disorders. By establishing clear requirements for coverage, the bill aims to enhance access to necessary medical evaluations and therapies for children suffering from these specific neuropsychiatric conditions. Such changes may alleviate previous barriers that families faced when seeking effective treatments, thereby improving overall health outcomes for children affected by these disorders.
Summary
House Bill 359 mandates that health plan issuers and the Medicaid program in Ohio provide coverage for treatments and services related to Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). This legislation seeks to ensure comprehensive health benefits for affected pediatric patients by requiring that health plans cover a range of treatments including diagnostic evaluations, immunomodulatory therapies, and therapeutic interventions. Furthermore, health plans cannot impose prior authorization requirements or step therapy protocols for these essential services.
Contention
Notably, discussions surrounding HB 359 may highlight varying opinions on the financial implications of mandated coverage. Proponents of the bill argue that it is essential for ensuring that children receive appropriate and timely care—a critical factor for effective treatment of PANDAS and PANS. However, some stakeholders may raise concerns regarding the potential increase in costs associated with expanded coverage for pediatric services, which could ultimately affect insurance premiums and the state's healthcare budget.